Mok J, Lee M, Kim DK, Kim JS, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial i Lancet 2022;400:1522-1530.
PMID: 36522208